HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

BEVZ92

a proposed biosimilar to bevacizumab

Networked: 1 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Abdalla, Kathia Cristina: 1 article (12/2018)
2.	Bondarenko, Igor: 1 article (12/2018)
3.	Del Campo García, Ana: 1 article (12/2018)
4.	Franke, Fábio: 1 article (12/2018)
5.	Huerga, Camino: 1 article (12/2018)
6.	Melo Cruz, Felipe: 1 article (12/2018)
7.	Mendonça Bariani, Giovanni: 1 article (12/2018)
8.	Millán, Susana: 1 article (12/2018)
9.	Ostwal, Vikas: 1 article (12/2018)
10.	Paravisini, Alexandra: 1 article (12/2018)

Related Diseases

1.	Colorectal Neoplasms (Colorectal Cancer) 12/01/2018 - "Our results suggest that BEVZ92 and reference bevacizumab are pharmacokinetically bioequivalent and have no appreciable differences in efficacy, immunogenicity, and safety profiles as first-line treatment in combination with FOLFOX or FOLFIRI in patients with metastatic colorectal cancer. " 12/01/2018 - "In this clinical study, we compared the pharmacokinetic profile, efficacy, safety, and immunogenicity of BEVZ92 with reference bevacizumab as a first-line treatment in patients with metastatic colorectal cancer. " 12/01/2018 - "Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial."
2.	Neutropenia 12/01/2018 - "Neutropenia was the most common grade 3 or 4 adverse event reported in the BEVZ92 (14 [20%] of 69 patients) and reference bevacizumab (19 [27%] of 71 patients) groups. "
3.	Intestinal Perforation 12/01/2018 - "Two patients died because of bevacizumab-related serious adverse events: a sudden death in the BEVZ92 group and a serious large intestinal perforation in the reference bevacizumab group. "
4.	Intestinal Obstruction (Obstruction, Intestinal) 12/01/2018 - "Two participants assigned to BEVZ92 did not receive treatment (one withdrew consent, the other had a serious intestinal obstruction before starting treatment); therefore, the treated population comprised 69 patients in the BEVZ92 group and 71 in the reference bevacizumab group. "
5.	Sudden Death 12/01/2018 - "Two patients died because of bevacizumab-related serious adverse events: a sudden death in the BEVZ92 group and a serious large intestinal perforation in the reference bevacizumab group. "

Related Drugs and Biologics

1.	Biosimilar Pharmaceuticals
2.	Bevacizumab (Avastin)